.Pharmacolibrary.Drugs.ATC.A.A10BD26 .Pharmacolibrary.Drugs.ATC.A.A10BD26| name: | MetforminAndLobeglitazone | |
| ATC code: | A10BD26 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 80 | L |
| clearance: | 15 | L/hr |
| other parameters in model implementation | ||
Metformin and lobeglitazone is a fixed-dose combination medication used in the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production and improves insulin sensitivity. Lobeglitazone is a thiazolidinedione (TZD) that acts as an insulin sensitizer by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ). The combination is designed to improve glycemic control in adults with type 2 diabetes. Lobeglitazone is approved mainly in South Korea and some Asian countries; the combination product is not widely approved outside these regions.
There are currently no published population pharmacokinetic models or clinical PK studies reported for the fixed-dose combination of metformin and lobeglitazone in peer-reviewed sources as of June 2024. Below are estimated pharmacokinetic parameters based on known properties of metformin and lobeglitazone administered orally in typical adult populations.